Cargando…

Serelaxin treatment reverses vascular dysfunction and left ventricular hypertrophy in a mouse model of Type 1 diabetes

Serelaxin prevents endothelial dysfunction in the mouse aorta ex vivo and inhibits apoptosis in cardiomyocytes under acute hyperglycaemia. Less is known about the effects of serelaxin in an in vivo mouse model of diabetes. Therefore, we tested the hypothesis in streptozotocin (STZ)-treated mice that...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ng, Hooi Hooi, Leo, Chen Huei, Prakoso, Darnel, Qin, Chengxue, Ritchie, Rebecca H., Parry, Laura J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2017
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5220363/ https://www.ncbi.nlm.nih.gov/pubmed/28067255 http://dx.doi.org/10.1038/srep39604

Ejemplares similares

Serelaxin Treatment Reduces Oxidative Stress and Increases Aldehyde Dehydrogenase-2 to Attenuate Nitrate Tolerance
por: Leo, Chen Huei, et al.
Publicado: (2017)

Relaxin as a Therapeutic Target for the Cardiovascular Complications of Diabetes
por: Ng, Hooi Hooi, et al.
Publicado: (2018)

Acute Intravenous Injection of Serelaxin (Recombinant Human Relaxin‐2) Causes Rapid and Sustained Bradykinin‐Mediated Vasorelaxation
por: Leo, Chen Huei, et al.
Publicado: (2014)

Serelaxin treatment promotes adaptive hypertrophy but does not prevent heart failure in experimental peripartum cardiomyopathy
por: Nonhoff, Justus, et al.
Publicado: (2017)

Serelaxin in acute heart failure patients with preserved left ventricular ejection fraction: results from the RELAX-AHF trial
por: Filippatos, Gerasimos, et al.
Publicado: (2014)

Association of Arterial Stiffness and Electrocardiography-Determined Left Ventricular Hypertrophy with Left Ventricular Diastolic Dysfunction
por: Hsu, Po-Chao, et al.
Publicado: (2012)

Echocardiographic assessment of inappropriate left ventricular mass and left ventricular hypertrophy in patients with diastolic dysfunction
por: Shemirani, Hasan, et al.
Publicado: (2012)

Serelaxin Elicits Bronchodilation and Enhances β-Adrenoceptor-Mediated Airway Relaxation
por: Lam, Maggie, et al.
Publicado: (2016)

FGF23/FGFR4-mediated left ventricular hypertrophy is reversible
por: Grabner, Alexander, et al.
Publicado: (2017)

Anabolic Androgenic Steroids Induce Reversible Left Ventricular Hypertrophy and Cardiac Dysfunction. Echocardiography Results of the HAARLEM Study
por: Smit, Diederik L., et al.
Publicado: (2021)

Adeno-associated viral (AAV) vector-mediated therapeutics for diabetic cardiomyopathy – current and future perspectives
por: Prakoso, Darnel, et al.
Publicado: (2021)

Lupus cardiomyopathy: a reversible form of left ventricular dysfunction
por: Ishimori, ML, et al.
Publicado: (2012)

The impact of obesity on left ventricular hypertrophy and diastolic dysfunction in children and adolescents
por: Bartkowiak, Joanna, et al.
Publicado: (2021)

Moexipril and left ventricular hypertrophy
por: Chrysant, George S, et al.
Publicado: (2007)

Left ventricular hypertrophy: is it really?
por: Mikolich, J Ronald, et al.
Publicado: (2013)

Differences in the renal antifibrotic signaling of serelaxin and zaprinast
por: Wetzl, Veronika, et al.
Publicado: (2015)

Vascular calcification and left ventricular hypertrophy in hemodialysis patients: interrelationship and clinical impacts
por: Hwang, Hyeon Seok, et al.
Publicado: (2018)

Association of echocardiographic measures of left ventricular diastolic dysfunction and hypertrophy with presence of coronary microvascular dysfunction
por: Dykun, Iryna, et al.
Publicado: (2020)

The Impact of Left Ventricular Hypertrophy and Diastolic Dysfunction on Outcome in Intracerebral Hemorrhage Patients
por: Albright, Karen C., et al.
Publicado: (2013)

Protection from cigarette smoke‐induced vascular injury by recombinant human relaxin‐2 (serelaxin)
por: Pini, Alessandro, et al.
Publicado: (2016)

Research Progress on the Efficacy and Safety of Spironolactone in Reversing Left Ventricular Hypertrophy in Hemodialysis Patients
por: Sun, Zuoya, et al.
Publicado: (2023)

Myocardial Energetics in Left Ventricular Hypertrophy
por: Jameel, Mohammad N, et al.
Publicado: (2009)

Reversible Left Ventricular Systolic Dysfunction Secondary to Pazopanib
por: Gajjar, Kushani, et al.
Publicado: (2018)

Left Ventricular Hypertrophy and Ventricular Tachyarrhythmia: The Role of Biomarkers
por: Bacharova, Ljuba, et al.
Publicado: (2023)

Left ventricular hypertrophy, diastolic dysfunction and right ventricular load predict outcome in moderate aortic stenosis
por: Stöbe, Stephan, et al.
Publicado: (2023)

Association between serum uric acid and left ventricular hypertrophy/left ventricular diastolic dysfunction in patients with chronic kidney disease
por: Kim, Il Young, et al.
Publicado: (2021)

Reversal of Right Ventricular Hypertrophy and Dysfunction by Prostacyclin in a Rat Model of Severe Pulmonary Arterial Hypertension
por: Vanderpool, Rebecca R., et al.
Publicado: (2022)

Platelet volume indices are associated with systolic and diastolic cardiac dysfunction, and left ventricular hypertrophy
por: Fujita, Shu-ichi, et al.
Publicado: (2015)

Association of Novel Biomarkers of Cardiovascular Stress With Left Ventricular Hypertrophy and Dysfunction: Implications for Screening
por: Xanthakis, Vanessa, et al.
Publicado: (2013)

Association of isolated minor nonspecific ST-T abnormalities with left ventricular hypertrophy and diastolic dysfunction
por: Kang, Jeong Gyu, et al.
Publicado: (2018)

Vascular effects of serelaxin in patients with stable coronary artery disease: a randomized placebo-controlled trial
por: Corcoran, David, et al.
Publicado: (2020)

Electrocardiographic Criteria for Left Ventricular Hypertrophy in Children
por: Rijnbeek, Peter R., et al.
Publicado: (2008)

The Role of ECG in the Diagnosis of Left Ventricular Hypertrophy
por: Bacharova, Ljuba, et al.
Publicado: (2014)

Left ventricular hypertrophy, inflammation, and insulin resistance
por: Öncel, Can Ramazan
Publicado: (2016)

Crim1 suppresses left ventricular hypertrophy
por: Yang, Long, et al.
Publicado: (2019)

Left ventricular apical hypertrophy (Yamaguchi disease)
por: Al Lawati, Hatim, et al.
Publicado: (2021)

Effect and correlation of patent vascular access flow on left ventricular hypertrophy in kidney transplant patients
por: Lukkanalikitkul, Eakalak, et al.
Publicado: (2022)

Quercetin prevents left ventricular hypertrophy in the Apo E knockout mouse()
por: Ulasova, Elena, et al.
Publicado: (2013)

Serelaxin as a potential treatment for renal dysfunction in cirrhosis: Preclinical evaluation and results of a randomized phase 2 trial
por: Snowdon, Victoria K., et al.
Publicado: (2017)

Metabolic Changes in Spontaneously Hypertensive Rat Hearts Precede Cardiac Dysfunction and Left Ventricular Hypertrophy
por: Li, Jie, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_5jpcfega8kkk5ech61ethcj8b6